A phase II clinical trial of carbon-ion radiotherapy using 12 fractions for prostate cancer
Phase 2
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000011631
- Lead Sponsor
- SAGA HIMAT foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients have received radiotherapy at the same position where carbon-ion radiotherapy is palanned. 2) Patients have received any kinds of therapies except hormonal therapy. 3) Patients have any other active malignancies. 4) Patients with active and intractable infection at the same position where carbon-ion radiotherapy is palanned. 5) Patients with evidence of elevation of PSA after starting of hormonal therapy and before starting of carbon-ion radiotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (biochemically or clinically) relapse free survival rate
- Secondary Outcome Measures
Name Time Method overall survival rate, cause-specific survival rate, normal tissue reaction, quality of life